Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)

The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).